title: Advances in management of meconium aspiration syndrome.
abstract: Meconium Aspiration Syndrome (MAS) is a leading cause of respiratory distress in the newborn. Antenatal diagnosis of meconium stained amniotic fluid and fetal distress is important to reduce morbidity and mortality in the neonates. Amnioinfusion of saline and tracheal suctioning of meconium are preventive interventions. Babies with MAS who continue to have respiratory distress need to be put on conventional ventilators. Increasing hypoxia, hypercarbia and barotrauma warrants changing to high frequency oscillatory ventilation. Pulmonary hypertension is an important complication which should be promptly recognized. Nitric oxide therapy used with high frequency ventilation has improved the outcome of babies with severe MAS and pulmonary hypertension. Some of these babies who continue to worsen clinically need to be put on ECMO circuit. Surfactant infusion in babies with MAS has been shown to improve gas exchange, resolve pulmonary hypertension and decrease oxygenation index. Total and partial liquid ventilation with perflurocarbon improves oxygenation, increases lung expansion and increases pulmonary blood flow in model studies of animals with MAS. Surfactant infusion and liquid ventilation are newer promising modes of therapeutic interventions in babies with severe MAS.
authors.affiliation: Driscoll Children's Hospital, 3533 South Alameda, Corpus Christi, Texas, USA. skhatua@aol.com
authors.forename: S
authors.initials: S
authors.lastname: Khatua
authors.forename: P R
authors.initials: PR
authors.lastname: Serrao
authors.forename: E L
authors.initials: EL
authors.lastname: Milano
mesh_terms: D015199:Extracorporeal Membrane Oxygenation; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D008471:Meconium Aspiration Syndrome / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D009569:Nitric Oxide / Q000627:therapeutic use; D010547:Persistent Fetal Circulation Syndrome / Q000209:etiology / Q000628:therapy; D011663:Pulmonary Surfactants / Q000627:therapeutic use*; D012119:Respiration; D012121:Respiration, Artificial / Q000379:methods; D012131:Respiratory Insufficiency / Q000209:etiology / Q000628:therapy; D012720:Severity of Illness Index
chemical_list: D011663:Pulmonary Surfactants; D009569:Nitric Oxide